Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge in 2015

SUGAR LAND--February 24, 2015--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Over the past decade, it has become obvious that the Pharmaceutical-Biotech Industry considers mergers and acquisitions (M&A) a key factor to growth, with billions of dollars on the table and occasional high-stakes drama. There appears to be no end in sight to this feeding frenzy for 2015. A scant two months into the year, and already several major deals are in play.

Within this article: Details on major deals in the year ahead, including those involving Valeant Pharmaceuticals (NYSE:VRX), Salix Pharmaceuticals (NASDAQ:SLXP), Shire (NASDAQ:SHPG), Pfizer Incorporated (NYSE:PFE) and Hospira (NYSE:HSP).

Other companies featured: Actavis (NYSE:ACT), AbbVie (NYSE:ABBV) and AstraZeneca plc (NYSE:AZN)